Compare Heron Therapeutics Inc (HRTX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Schlumberger NV — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while Schlumberger NV trades at $53.67 (market cap $78.96B). The key difference: Schlumberger NV is far larger — about 1245.2× Heron Therapeutics Inc's market cap, and Schlumberger NV pays a 2.22% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SLB | |
|---|---|---|
Market Cap | $63.41M | $78.96B |
Sector | Health | Energy |
52-Week High | $1.49 | $58.01 |
52-Week Low | $0.33 | $31.72 |
Enterprise Value | $161.31M | $87.68B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
SLB's stock trades at $50.53, down 1.96% over the past day, but maintains a bullish technical signal with strong moving average support. The company recently reported Q2 2026 earnings of $0.55 per share, beating estimates, and has a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53% and a P/E ratio of 24.65.
The outlook for SLB is positive, driven by growth in offshore, digital, and production segments, though risks include Middle East volatility and net debt levels. With 85% of analysts rating it a buy and a dividend yield supported by recent payments, the stock presents a compelling opportunity for investors seeking energy sector exposure with solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
